Exclusive
Wellness Benefits
24*7 Claims
Support
Tax Savings
u/s 80D
Try agian later
I agree to the Terms & Conditions
Analysing your health details
Please wait a moment....
Terms and conditions
Terms and conditions
Nuchal translucency or NT scan helps determine a baby's risk of developing congenital conditions, such as Down syndrome. Its accuracy is high when performed along with other screenings at first-trimester.
However, it is necessary to understand that the Nuchal translucency test does not diagnose a condition. It rather helps doctors assume the possible risks of a genetic or chromosomal condition based on how the fluid behind a baby’s neck appears. More fluid may result in the mentioned conditions.
Nuchal translucency is an ultrasound that measures the fluid present behind a baby's neck in the first trimester of pregnancy. Test reports are normal when a small amount of fluid is present behind the baby's neck. Conversely, when the fluid amount is high, it suggests the baby is at a heightened risk of developing a genetic or chromosomal variant.
The purpose of nuchal translucency is to determine whether a baby has developed with a normal nucleus containing 23 chromosomes inherited equally from both parents. The test otherwise suggests- a baby developing with an extra copy of chromosome 21 develops Down syndrome.
A healthcare professional performs an NT scan procedure when a baby is between 45 to 84 millimetres from its head to its torso or 11 to 13 weeks of gestation. The test is performed at this stage, given that the fluid behind a baby's neck has a tendency to get reabsorbed after 14 weeks of gestation.
Nuchal translucency ultrasound can be done through a mother’s vagina or abdomen.
However, when the scan is performed trans-vaginally, it takes the sonographer to drive the probe internally in a gentle manner. This may cause some discomfort, and usually is not painful. In addition, this process gives better and clearer pictures as the probe is closer to the uterus.
Nuchal translucency is measured in the sagittal plane at its maximal thickness. Therefore, the nuchal translucency measurement may have multiple ways of expression. One way is- reporting the difference in millimetres between the normal median for the CRL (Crown-Rump length) and the measured nuchal translucency.
Screening performed via NT scan is known to be 85% accurate for predicting risks of trisomy 21 and other conditions. However, it is crucial to have tests done beforehand to understand possible risks, seek treatment at the earliest, and be aware and prepared to determine how to bring up a baby with chromosomal conditions.
It usually takes 20-40 minutes for a complete nuchal translucency scan.
It usually takes 20-40 minutes for a complete nuchal translucency scan.
The nuchal translucency test results are usually ready in 1-2 days.
The nuchal translucency test results are usually ready in 1-2 days.
Yes. NT scan is completely safe for the baby as it is a non-invasive test. Also, it is an optional procedure which you may or may not carry during your pregnancy.
Yes. NT scan is completely safe for the baby as it is a non-invasive test. Also, it is an optional procedure which you may or may not carry during your pregnancy.
Please try one more time!
Other Important Articles about Procedures & Tests
Currently there are no news to show.
09-01-2025
Research from Second Pig Heart Transplant Provides New Directions for Xenotransplantation
Surgeon-scientists at the University of Maryland School of Medicine analyzed the second-ever genetically-modified pig heart transplant. Lawrence Faucette, 58, received the pig heart in 2023 and lived for 40 days before rejection led to transplant failure. The study, published in Nature Medicine, highlights initial rejection signs and the need for ongoing research to overcome challenges like antibody-mediated rejection. This case underscores the importance of continued advancements in xenotransplantation for future clinical trials.
30-11-2024
Making Fertility Treatments Easier for All in India
Infertility in India is a complex issue due to limited access to clinics in rural areas and societal stigma. With 10-15% of couples affected, addressing infertility requires more than medical solutions. It's crucial to break taboos, raise awareness, and improve access to treatments, emphasizing the importance of family and parenthood. Efforts must focus on developing infrastructure, training professionals, and increasing affordability through financial assistance and government subsidies to make fertility care accessible for all.
26-11-2024
Medtronic's Interstim X Now FDA Approved in India
Sacral neuromodulation targets nerve signals to control bladder functions, reducing incontinence symptoms. Medtronic launched the InterStim X system in India for treating overactive bladder, fecal incontinence, and urinary retention. Patients can try the system before permanent implantation, which involves a two-stage procedure. The device features a long-lasting battery and a smart programmer for therapy adjustments. It's backed by extensive clinical research and offers MRI compatibility. The therapy aims to improve bladder and bowel control for patients in India.
17-10-2024
ICMR’s New Research Partnerships
The Indian Council of Medical Research (ICMR) has signed MoUs with various entities to enhance India’s clinical research. Collaborations include developing treatments for multiple myeloma, Zika, seasonal influenza, and chronic lymphocytic leukemia. The initiative involves institutions across India and aims to create affordable, accessible therapies for various diseases.
25-09-2024
Aster MIMS Concludes Kerala's First Medical Robo Expo
Aster MIMS in Calicut recently concluded Kerala's first Medical Robo Expo on April 26, 2024. The event showcased advanced technologies like the Da Vinci Robotic Surgical System and the 3 Tesla MRI system, which offer minimally invasive procedures and superior imaging capabilities. These innovations continue to enhance patient care, demonstrating the future of medical technology in the region.
23-09-2024
Blood Test for Obesity Risks in Kids
A new blood test can identify children at risk of obesity-related conditions by analyzing various lipid molecules, not just cholesterol. The study found new lipids linked to health risks like high blood pressure. This test could help detect early signs of diabetes and heart disease in children.
17-09-2024
IIT-Madras Develops Portable Ultrasound Scanner
Researchers at IIT-Madras have developed a portable Point-of-Care-Ultrasound (POCUS) scanner for diagnosing sports injuries. This AI-powered device allows for on-field injury assessment, helping medical professionals decide if athletes can continue playing. The scanner emits no radiation and is set for prototype completion by 2024. The team, led by Prof. Arun K. Thittai, aims to integrate the scanner into a broader AI platform for athlete management. Testing and data collection are planned in collaboration with sports authorities.
13-09-2024
India to Develop Zika Vaccine
Indian Immunologicals and Indian Council of Medical Research (ICMR)R have signed an agreement to develop India’s first codon de-optimised live attenuated Zika vaccine. ICMR will fund phase I clinical trials, which will be conducted at its network sites. This vaccine aims to address the currently unmet need for a Zika vaccine.
07-09-2024
Government Enforces New Marketing Code for Medical Devices
The Central Government has issued the Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024 to prevent unethical practices. The code bans promoting medical devices before regulatory approval and prohibits offering hospitality or monetary benefits to healthcare professionals. Companies must disclose expenses for conferences and workshops and display the code on their websites. The Department of Pharmaceuticals (DoP) requires the formation of ethics committees to ensure compliance. This initiative promotes ethical marketing and transparency in the medical device industry.
01-08-2024
Experts Call for Enhanced Lung Cancer Screening in India
India faces a rising lung cancer burden with high mortality rates, primarily due to late detections. The absence of a systematic screening program contributes to this issue. Experts advocate for implementing Low-Dose Computed Tomography (LDCT) to detect cancers early and improve survival rates. Challenges include cost and logistics, but developing a national screening framework could address these issues and enhance patient outcomes.
Read More
Renew & Download Policy Document, Check Challan, Credit Score, PUC & more
Anytime, Anywhere. Only on Digit App!
4.8
Rated App51K+ Reviews
4.8
Rated App
51K+ Reviews
4.3
Rated App10K+ Reviews
4.3
Rated App
10K+ Reviews
Scan to Download
Author: Team Digit
Last updated: 23-02-2025
CIN: U66010PN2016PLC167410, IRDAI Reg. No. 158.
Go Digit General Insurance Limited (formerly known as Oben General Insurance Ltd.) - Registered Office Address - 1 to 6 floors, Ananta One (AR One), Pride Hotel Lane, Narveer Tanaji Wadi, City Survey No.1579, Shivaji Nagar, Pune-411005, Maharashtra | Corporate Office Address - Atlantis, 95, 4th B Cross Road, Koramangala Industrial Layout, 5th Block, Bengaluru-560095, Karnataka | Trade logo of Go Digit General Insurance Ltd. displayed above belongs to Go Digit lnfoworks Services Private Limited and is provided and used by Go Digit General Insurance Ltd. under license.